VKTX — Viking Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Viking Therapeutics Q2 EPS USD -1.1 Vs. IBES Estimate USD -1.25
Viking Therapeutics Inc expected to post a loss of $1.25 a share - Earnings Preview
Factbox: Race to launch weight-loss pills heats up as smaller players advance
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
U.S. STOCKS ON THE MOVE-Broadcom, Micron, Qualcomm
Viking Therapeutics gains after initiating Phase 1 trial for new weight-loss drug
Brief: Viking Therapeutics Announces Initiation Of Phase 1 Study To Evaluate Novel Amylin Receptor Agonist Vk3019 In Healthy Adults
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Viking Therapeutics Announces Appointment Of Hubert C. Chen, M.D., As Chief Medical Officer
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Viking Therapeutics Presents Data From Its 13-Week Phase 2 Venture-Oral Dosing Trial
Viking Therapeutics Q1 loss widens on higher research, development expenses
Brief: Viking Therapeutics Q1 EPS USD -1.37 Vs. IBES Estimate USD -1.01
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Lilly gains after FDA approves weight-loss pill, sizing down investor doubts
Eli Lilly rises after US FDA approves weight-loss pill
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval